Albany, NY -- (SBWIRE) -- 10/07/2015 -- New report on "Psoriasis Therapeutics in Asia-Pacific Markets to 2021: Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth" provides insights into psoriasis therapeutics in the Asia-Pacific (APAC) market. For the purposes of this report, APAC refers to the market in China, India, Japan, and Australia only. The report estimates the market size for 2014, along with forecasts until 2021. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of pipeline molecules, clinical trial failure rates, and analysis of recent deals.
In 2014, the value of the psoriasis therapeutics market in APAC amounted to an estimated $690m, and it is forecast to grow at a Compound Annual Growth Rate (CAGR) of 8.4% between 2014 and 2021 to reach $1.2 billion. The psoriasis treatment landscape is a particularly complex one. More than 80% of patients fall into the mild-or-moderate category, for which the first line of treatment is topical drugs, phototherapy, or a combination. In the case of severe patients, non-steroidal drugs such as methotrexate, cyclosporine, and acitretin are practiced as first-line treatment; however, they come with toxicity concerns and so cannot be prescribed for long durations.
Download Free Sample report with report structure at: http://www.researchmoz.us/enquiry.php?type=S&repid=285644
Biologics such as TNF inhibitors (adalimumab, etanercept, infliximab) and ustekinumab are largely prescribed as second-line therapy when none of the aforementioned options provide the desired results. However, during the forecast period, biologics are likely gain a significant patient share due to healthcare plans in APAC and awareness regarding the effectiveness of biologics. Among the recently launched biologics, Cosentyx (secukinumab) from Novartis has shown better efficacy than Enbrel (etanercept), and is a novel molecule that targets Interluekin-17 (IL-7). Biocon India has launched Alzumab (itolizumab), which is a first-in-class novel molecule that targets CD6 protein. It is anticipated to be the leading biologic in India by the end of forecast period. Humira (adalimumab), Enbrel (etanercept), and Remicade (infliximab) are expected to lose their patent during the forecast period, but will be compensated for by biosimilar versions.
Browse Complete report description with TOC: http://www.researchmoz.us/psoriasis-therapeutics-in-asia-pacific-markets-to-2021-advent-of-novel-biologics-and-expanding-treatment-pool-to-drive-growth-report.html
Reasons to buy:
The report will enhance your decision-making capability by allowing you to:
Understand the psoriasis pipeline and the factors that indicate that it is becoming more innovative
Analyze detailed profiles for promising pipeline products and gain insights into how they are likely to compete in the market and who their main competitors will be
Follow the trends in psoriasis clinical trial size and duration in relation to industry averages
Assess the potential risk of future developmental programs for psoriasis therapeutics by mechanism of action using recorded clinical trial failure rates
Analyze the potential growth patterns expected for the psoriasis market over the forecast period
Identify the countries that are expected to contribute the most to this growth and devise a more effectively tailored country strategy through an understanding of key drivers and barriers
Accelerate and strengthen your market position by identifying key companies for strategic partnerships
Click for Query/ Enquiry: http://www.researchmoz.us/enquiry.php?type=enquiry&repid=285644
Similar Reports:-
Moderate Psoriasis Global Clinical Trials Review, H2
http://www.researchmoz.us/moderate-psoriasis-global-clinical-trials-review-h2-2014-report.html
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2015
http://www.researchmoz.us/plaque-psoriasis-psoriasis-vulgaris-pipeline-review-h1-2015-report.html
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket
Albany NY - 12207
United States
Tel: +1-518-621-2074
Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us